Middle East conflict impact on logistics and glass costs
Management noted potential 1-2% revenue impact from Middle East conflict-related logistics disruptions and glass cost inflation of 5-6%.
medium · management_commentaryGland Pharma Limited — Q4 FY26
Gland Pharma delivered a strong Q4 FY26 with consolidated revenue of ₹1,742.8 crore (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDMO growth (46%...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
GLP-1 revenue uncertainty and delayed ramp-up
GLP-1 revenue not included in FY27 guidance due to uncertainty in partner approvals and market timing; ramp-up expected only post-2030.
medium · analyst_questionSenXi revenue growth may be modest despite margin improvement
SenXi's revenue increase may not be significant as focus is on replacing low-value products with high-value ones; FY27 revenue may only approach €200M.
low · analyst_questionBase business margin sustainability at elevated Q4 levels
Q4 base business EBITDA margin of 41% may not be sustainable; management guided for 35% for FY27, implying normalization.
medium · data_observation